Skip to main content

MODULACION FARMACOLOGICA DEL REMODELADO DE VIAS AEREAS Y VASO PULMONAR: NUEVAS DIANAS EN MODELOS HUMANOS/ANIMALES

SAF2009-08913

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2009
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Subdirección General de Proyectos de Investigación
Beneficiary centre UNIVERSITAT DE VALÈNCIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Cigarette smoke exposure up-regulates endothelin receptor B in human pulmonary artery endothelial cells: molecular and functional consequences

  • Milara, J
  • Ortiz, JL
  • Juan, G
  • Guijarro, R
  • Martorell, M
  • Morcillo, EJ
  • Cortijo, J
  • Almudéver-Folch, Patricia|||0000-0003-3138-0862
[EN] Background and purpose: Pulmonary arteries from smokers and chronic obstructive pulmonary disease patients show abnormal endothelium-dependent vascular reactivity. We studied the effect of cigarette smoke extract (CSE) on endothelin receptor B (ET(B) ) expression in human pulmonary artery endothelial cells (HPAECs) and its role in endothelial dysfunction. Experimental approach: ET(B) receptor expression was measured by real time RT-PCR, Western blot and immunofluorescence. Cell contraction, intracellular Ca(2+) , F/G-actin, RhoA activity, myosin light chain phosphorylation, ET, NO, thromboxane (Tx)A(2) and reactive oxygen species (ROS) were measured by traction microscopy, fluorescence microscopy, phalloidin fluorescence, colorimetric assay, Western blot, elisa and DCFDA fluorescence respectively. Key results: Cigarette smoke extract dose-dependently increased ET(B) receptor expression in HPAECs after 24h incubation. CSE-induced ET(B) expression was attenuated by bosentan, the ET(B) receptor antagonist BQ788, the Rho kinase antagonist Y27632 and the antioxidant N-acetylcysteine. A monoclonal antibody to ET-1 prevented CSE-induced ET(B) receptor overexpression. Twenty-four hour exposure to ET-1 dose-dependently increased ET(B) receptor expression, mimicking the effect of CSE. CSE-induced ET(B) receptor overexpression caused greater cell contraction; increased intracellular Ca(2+) ; increased F/G-actin and RhoA activity; increased myosin light chain phosphorylation; augmented TxA(2) and ROS production; and decreased NO after acute ET-1 (10nM). These effects were attenuated by bosentan, BQ788, Y27632 and N-acetylcysteine. Conclusions and implication: Cigarette smoke extract induced ET(B) receptor overexpression by a feed forward mechanism mediated partly by ET release, promoting HPAEC dysfunction and attenuated by ET(B) receptor blockade, Rho kinase and ROS inhibition. These results provide support for the use of bosentan in CS-related endothelial dysfunction., This work was supported by grants SAF2008-03113 (JC), SAF2009-08913 (EJM), CIBERES (CB06/06/0027) from Ministry of Science and Innovation and Health Institute 'Carlos III' of Spanish Government, and research grants (Prometeo/2008/045) from Regional Government ('Generalitat Valenciana'). This work was partly supported by Actelion Pharmaceuticals Ltd, Switzerland who provided bosentan.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages

  • Milara, J.
  • Navarro, A.
  • Lluch, J.
  • Morcillo, E. J.
  • Cortijo, J.
  • Almudéver-Folch, Patricia|||0000-0003-3138-0862
[EN] Background Oxidative stress is present in airway diseases such as severe asthma or Chronic Obstructive Pulmonary Disease and contributes to the low response to glucocorticoids through the down-regulation of histone deacetylase (HDAC) activity. Objective To study the effects of the phosphodiesterase (PDE)-3 and 4 inhibitors and their combination vs. glucocorticoids in a model of lipopolysaccharide (LPS)-induced cytokine release in alveolar macrophages under oxidative stress conditions. Methods Differentiated U937 or human alveolar macrophages were stimulated with H2O2 (10¿1000¿¿m) or cigarette smoke extract (CSE, 0¿15%) for 4¿h before LPS (0.5¿¿g/mL, 24¿h) addition. In other experiments, cells were pre-treated with dexamethasone or budesonide (10¿9¿10¿6¿m), with the PDE4 inhibitor rolipram (10¿9¿10¿5¿m), PDE3 inhibitor motapizone (10¿¿m), 3¿,5¿-cyclic monophosphate enhancer PGE2 (10¿nm), or with the combination of rolipram (10¿6¿m)+PGE2 (10¿nm)+motapizone (10¿¿m) 15¿min before oxidants. IL-8 and TNF-¿ were measured by ELISA and HDAC activity by a colorimetric assay. Results Budesonide and dexamethasone produced a concentration-dependent inhibition of the LPS-induced IL-8 and TNF-¿ secretion with an Emax about 90% of inhibition, which was reduced by approximately 30% in the presence of H2O2 or CSE. Pre-treatment with rolipram, motapizone or PGE2 only reached about 20% of inhibition but was not affected by oxidative stress. In contrast, PDE4/PDE3 combination in presence of PGE2 effectively inhibited the LPS-induced cytokine secretion by about 90% and was not affected by oxidative stress. Combined PDE4 and PDE3 inhibition reversed glucocorticoid resistance under oxidative stress conditions. HDAC activity was reduced in the presence of oxidative stress, and in contrast to glucocorticoids, pre-treatment with PDE4/PDE3 combination was able to prevent HDAC inactivity. Conclusions & Clinical Relevance This study shows that the combination of the PDE3/PDE4 inhibitors prevents alveolar macrophage activation in those situations of glucocorticoid resistance, which may be of potential interest to develop new effective anti-inflammatory drugs in airway diseases., This work was supported by grants SAF2008-03113 (JC), SAF2009-08913 (EJM), and CIBERES (CB06/06/0027) from the Ministry of Science and Innovation and Health Institute 'Carlos III' of Spanish Government, and research grants (Prometeo/2008/045 and Emerging Groups GE-029/10) from the Regional Government ('Generalitat Valenciana').